TransMedics grew sales by 38% during the second quarter and saw its profit margins double compared to last year. Despite this, there may still be room for improvement, according to its CEO.

TransMedics Group (NASDAQ: TMDX) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August. Unfortunately, shares of the healthcare stock ...

TransMedics' stock is overvalued despite recent revenue growth, with a 25% annual growth rate priced in, while the transplant market grows at 8.5% CAGR. The company faces stiff competition from ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

TransMedics Group's Organ Care System (OCS) is transforming organ transplantation. The company should be well-positioned to dominate the organ transplant market for decades. TransMedics believes it ...

Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence. TransMedics reported ...